Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial
Diabetes, Obesity and Metabolism Jan 05, 2018
Pettus J, et al. - The experts undertook this study to investigate the efficacy and safety of glucagon receptor antibody (REMD-477), a glucagon receptor antagonist, in type 1 diabetes. Among patients with type 1 diabetes, glucagon receptor antagonism decreased insulin requirements and improved glycemic control.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
